Craigavon Cardiac Centre, Southern Trust, Craigavon, Northern Ireland, UK.
Adv Ther. 2018 Jul;35(7):899-927. doi: 10.1007/s12325-018-0716-y. Epub 2018 Jun 14.
Numerous important cardiology clinical trials have been published or presented at major international meetings during 2017. This paper aims to summarize these trials and place them in clinical context.
The authors reviewed clinical trials presented at major cardiology conferences during 2017 including the American College of Cardiology, European Association for Percutaneous Cardiovascular Interventions, European Society of Cardiology, European Association for the Study of Diabetes, Transcatheter Cardiovascular Therapeutics, and the American Heart Association. Selection criteria were trials with a broad relevance to the cardiology community and those with potential to change current practice.
A total of 75 key cardiology clinical trials were identified for inclusion. New interventional and structural cardiology data include left main bifurcation treatment strategy, multivessel disease management in cardiogenic shock, drug-eluting balloons for in-stent restenosis, instantaneous wave-free physiological assessment, new-generation stents (COMBO, Orsiro), transcatheter aortic valve implantation, and closure devices. New preventative cardiology data include trials of liraglutide, empagliflozin, PCSK9 inhibitors (evolocumab and bococizumab), inclisiran, and anacetrapib. Antiplatelet data include the role of uninterrupted aspirin therapy during non-cardiac surgery and dual antiplatelet therapy following coronary artery bypass grafting. New data are also included from fields of heart failure (levosimendan, spironolactone), atrial fibrillation (apixaban in DC cardioversion), cardiac devices (closed loop stimulation pacing for neuromediated syncope), and electrophysiology (catheter ablation for atrial fibrillation).
This paper presents a summary of key clinical cardiology trials during the past year and should be of practical value to both clinicians and cardiology researchers.
2017 年期间，许多重要的心脏病学临床试验已在主要国际会议上发表或展示。本文旨在总结这些试验，并将其置于临床背景下。
作者回顾了 2017 年在主要心脏病学会议上展示的临床试验，包括美国心脏病学会、欧洲经皮心血管介入学会、欧洲心脏病学会、欧洲糖尿病研究协会、经导管心血管治疗学会和美国心脏协会。选择标准是对心脏病学界具有广泛相关性且有可能改变当前实践的试验。
共确定了 75 项关键的心脏病学临床试验纳入研究。新的介入心脏病学和结构性心脏病学数据包括左主干分叉治疗策略、心源性休克多血管疾病管理、药物洗脱球囊治疗支架内再狭窄、瞬时无波生理评估、新一代支架（COMBO、Orsiro）、经导管主动脉瓣植入术和封堵装置。新的预防心脏病学数据包括利拉鲁肽、恩格列净、PCSK9 抑制剂（依洛尤单抗和波考立珠单抗）、inclisiran 和 anacetrapib 的临床试验。抗血小板数据包括非心脏手术期间不间断阿司匹林治疗和冠状动脉旁路移植术后双联抗血小板治疗的作用。心力衰竭领域（左西孟旦、螺内酯）、心房颤动（依伐卡班在直流电复律中的应用）、心脏装置（神经介导性晕厥闭环刺激起搏）和电生理学（心房颤动导管消融）也有新数据。
本文总结了过去一年中关键的临床心脏病学试验，对临床医生和心脏病学研究人员都具有实际价值。
